1. Search Result
Search Result
Results for "

heterodimer

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

3

Inhibitory Antibodies

2

Natural
Products

98

Recombinant Proteins

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99676

    SI-B001

    EGFR Cancer
    Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
    Izalontamab
  • HY-125978

    c-Myc Cancer
    JY-3-094 is a Myc inhibitor that inhibits Myc-Max heterodimer formation (IC50: 33 μM) .
    JY-3-094
  • HY-149536

    Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .
    TWIK-1/TREK-1-IN-1
  • HY-142943

    DNA-PK Cancer
    DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021136463A1, compound 1) .
    DNA-PK-IN-1
  • HY-142944

    DNA-PK Cancer
    DNA-PK-IN-2 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2021136462A1, compound 1) .
    DNA-PK-IN-2
  • HY-Y1666

    Biochemical Assay Reagents Others
    2,2′-Dipyridyl disulfide is a useful reagent for the determination of sulfhydryl groups. 2,2′-Dipyridyl disulfide is a common reagent in peptide chemistry, often used in oxidation–reduction condensations to form peptide bonds or in coupling reactions to form disulfide-linked heterodimers .
    2,2′-Dipyridyl disulfide
  • HY-P3229
    SN52
    1 Publications Verification

    NF-κB Cancer
    SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .
    SN52
  • HY-P99184

    Integrin Infection Inflammation/Immunology Cancer
    Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
    Abrilumab
  • HY-163333

    Integrin Apoptosis Cancer
    αvβ5 integrin-IN-2 (Cpd_AV2) is an αvβ5 integrin inhibitor that disrupts the stability of integrin heterodimers. αvβ5 integrin-IN-2 targets the β-propeller central pocket of ITGAV (integrin αV). αvβ5 integrin-IN-2 induces cellular apoptosis .
    αvβ5 integrin-IN-2
  • HY-122683
    sAJM589
    1 Publications Verification

    c-Myc Cancer
    sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM .
    sAJM589
  • HY-P1275
    Tertiapin-Q
    2 Publications Verification

    Potassium Channel Cardiovascular Disease
    Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir1.1).
    Tertiapin-Q
  • HY-115672
    KS15
    1 Publications Verification

    Cryptochrome Cancer
    KS15 is an inhibitor of the interactions between cryptochromes (CRYs: CRY1 and CRY2) and the CLOCK:BMAL1 heterodimer. KS15 impairs the feedback actions of CRYs on E-box-dependent transcription (EC50=4.9 μM) by CLOCK:BMAL1 heterodimer, an indispensable transcriptional regulator of the mammalian circadian clock. Anti-proliferative activity .
    KS15
  • HY-17029
    Epothilone B
    5 Publications Verification

    EPO 906; Patupilone

    Microtubule/Tubulin Fungal Apoptosis Antibiotic Bacterial Infection Cancer
    Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.
    Epothilone B
  • HY-134400

    Others Endocrinology
    Follicle-stimulating hormone is a heterodimer glycoprotein expressed by gonadotropin in the anterior pituitary gland. Follicle-stimulating hormone affects the fertility and reproductive efficiency of animals .
    Follicle-stimulating hormone
  • HY-112374

    Others Neurological Disease
    NPAS3-IN-1 is a potent inhibitor of NPAS3-ARNT heterodimerization and regulates NPAS3 transcription by disrupting the heterodimerization of NPAS3 with ARNT at the cellular level .
    NPAS3-IN-1
  • HY-120875

    RAR/RXR Neurological Disease
    HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity .
    HX600
  • HY-19466

    TD-1792

    Cefilavancin (TD-1792) is a potent multivalent glycopeptide-cephalosporin heterodimer antibiotic with effective activity against Gram-positive bacteria. Cefilavancin has been used to research skin infections .
    Cefilavancin
  • HY-121896

    SHP2 Cancer
    DSHN is a potent small heterodimer partner (SHP) activator. DSHN inhibits Ccl2 expression and secretion by inhibiting p65 activation of Ccl2 promoter activity. DSHN can be used in research of cancer .
    DSHN
  • HY-104006

    Opioid Receptor Neurological Disease
    CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC50 of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .
    CYM51010
  • HY-108523

    UVI 2112

    RAR/RXR Metabolic Disease
    LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .
    LG100754
  • HY-19528
    SAH
    Maximum Cited Publications
    6 Publications Verification

    SAH (S-Adenosylhomocysteine)

    Endogenous Metabolite Metabolic Disease
    SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM .
    SAH
  • HY-149538

    Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .
    TWIK-1/TREK-1-IN-3
  • HY-122727
    STL127705
    4 Publications Verification

    DNA-PK Apoptosis Cancer
    STL127705 (Compound L) is a potent Ku 70/80 heterodimer protein inhibitor with an IC50 of 3.5 μM. STL127705 interferes the binding of Ku70/80 to DNA and by inhibits the activation of the DNA-PKCS kinase. STL127705 shows antiproliferative and anticancer activity. STL127705 induces apoptosis .
    STL127705
  • HY-19528S

    SAH (S-Adenosylhomocysteine)-d4

    Endogenous Metabolite Metabolic Disease
    SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].
    SAH-d4
  • HY-19528S1

    SAH (S-Adenosylhomocysteine)-13C5

    Endogenous Metabolite Metabolic Disease
    SAH- 13C5 is the 13C-labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].
    SAH-13C5
  • HY-E70080

    Biochemical Assay Reagents Others
    Vaccinia virus capping enzyme is a transcription initiation factor. Vaccinia virus capping enzyme is a heterodimer of D1 (844 aa) and D12 (287 aa) polypeptides that executes all three steps in m7GpppRNA synthesis. Vaccinia virus capping enzyme has been used widely as a reagent for capping and cap-labeling RNAs in vitro .
    Vaccinia virus capping enzyme
  • HY-19528S2

    Endogenous Metabolite Metabolic Disease
    SAH- 13C10 is the 13C labeled SAH[1]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[2]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[3].
    SAH-13C10
  • HY-155160

    Lipoxygenase COX Inflammation/Immunology
    COX-2/15-LOX-IN-3 (compound 5k) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-3 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS, and NO), with specific anti-inflammatory activity .
    COX-2/15-LOX-IN-3
  • HY-155161

    Lipoxygenase COX Inflammation/Immunology
    COX-2/15-LOX-IN-4 (compound 5i) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-4 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS) with specific anti-inflammatory activity .
    COX-2/15-LOX-IN-4
  • HY-150511

    Microtubule/Tubulin Apoptosis Cancer
    3-(3-Phenoxybenzyl)amino-β-carboline is a potent tubulin inhibitor. 3-(3-Phenoxybenzyl)amino-β-carboline promotes selective degradation of αβ-tubulin heterodimers. 3-(3-Phenoxybenzyl)amino-β-carboline induces G2/M phase cell cycle arrest and apoptosis. 3-(3-Phenoxybenzyl)amino-β-carboline exhibits anticancer activity .
    3-(3-Phenoxybenzyl)amino-β-carboline
  • HY-158115

    Molecular Glues Raf MEK Cancer
    NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .
    NST-628
  • HY-149537

    Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-2 (Compound 2g) is a TWIK-1/TREK-1 inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant .
    TWIK-1/TREK-1-IN-2
  • HY-110353
    CU-T12-9
    3 Publications Verification

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    CU-T12-9 is a specific TLR1/2 agonist with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS .
    CU-T12-9
  • HY-15128

    Alitretinoin

    RAR/RXR Apoptosis Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities .
    9-cis-Retinoic acid
  • HY-150096

    NDI-034858; TAK-279

    JAK Inflammation/Immunology
    Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM .
    Zasocitinib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: